ABout US

At Nimbus, we design breakthrough medicines.

 

We apply our unique collective expertise to design small molecule therapeutics.

 

We push the leading edge to solve drug discovery’s big challenges and create breakthroughs.

 

And we strive to develop meaningful medicines for patients.

board of directors

Bruce Booth, Ph.D.

Chairman of the Board
Partner, Life Sciences
Atlas Venture

VIEW bio
Jean George, MBA

General Partner
Lightstone Ventures

VIEW bio
Ramy Farid, Ph.D.

President & CEO
Schrödinger

VIEW bio
Rajeev Dadoo, Ph.D., MBA

Partner
SR One Ltd.

VIEW bio
Steve Hall, Ph.D.

General Partner
Lilly Ventures

VIEW bio
Mark Iwicki

Chairman and CEO
Kala Pharmaceuticals

VIEW bio
Nikola Trbovic, Ph.D.

Executive Director, WRD and Principal
Pfizer Ventures

VIEW bio
Jeb Keiper, M.S., MBA

CEO
Nimbus Therapeutics

VIEW bio
George P. Vlasuk, Ph.D.

President and CSO
Navitor Pharmaceuticals

VIEW bio

Investors

Nimbus Therapeutics is backed by world-class life science investors, including Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments and Lightstone Ventures. The company closed a $24 million Series A financing in June 2011, a $43 million Series B financing in March 2015, and an additional $65 million in financing in June 2018.

x

Bruce Booth, Ph.D.

Chairman of the Board
Partner, Life Sciences
Atlas Venture

Bruce Booth is a partner and focuses on the discovery and development of novel medicines and therapeutic platforms. Bruce is currently chairman of AVROBIO (NASDAQ:AVRO), Kymera Therapeutics, Hotspot Therapeutics, Nimbus Therapeutics, Rodin Therapeutics, and Unum Therapeutics (NASDAQ:UMRX), and also serves on the boards of Lysosomal Therapeutics and Magenta Therapeutics (NASDAQ:MGTA). He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), Zafgen (NASDAQ:ZFGN), and a number of other ventures. Bruce serves as an advisor in various capacities to UCB, Takeda, and the Gates Foundation. He also serves on the boards of the National Venture Capital Association, the Pennsylvania State Research Foundation, and New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes. Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (Ph.D.) in molecular immunology from Oxford University. He received a B.S. in biochemistry, summa cum laude, from The Pennsylvania State University. Bruce enjoys running, skiing, hiking, and fly fishing. He lives in Wellesley, MA and has three wonderful kids.

Jean George, MBA

General Partner
Lightstone Ventures

Jean is a General Partner of Lightstone Ventures. She focuses on biopharmaceutical and medical device investments out of the firm’s Boston, MA, office. She also serves as a General Partner of Advanced Technology Ventures (ATV). Her representative investments include Acceleron Pharma (NASDAQ: XLRN), Calithera Biosciences (NASDAQ: CALA), Catabasis Pharmaceuticals (NASDAQ: CATB), Cyteir Therapeutics, Disarm Therapeutics, Flex Pharma (NASDAQ: FLKS), Five Prime Therapeutics (NASDAQ: FPRX), Gemini Therapeutics, Hydra Biosciences, Hypnion (acquired by Eli Lilly), Locana Therapeutics, Portola Pharmaceuticals (NASDAQ: PTLA), Proteolix (acquired by Onyx Pharmaceuticals), Tizona Therapetics, Verastem (NASDAQ: VSTM), and Zeltiq Aesthetics (NASDAQ: ZLTQ). Jean has been featured on the Forbes Midas List and was previously a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. Prior to LSV and ATV, Jean worked for BancBoston Ventures and led its life sciences investments in Neurometrix (NASDAQ:NURO), Ironwood Pharmaceuticals (NASDAQ: IRWD), NuGenesis Technologies (acquired by Waters) and Syntonix Pharmaceuticals (acquired by Biogen/Idec). Jean has been in the biopharmaceutical industry for over 30 years. She received an MBA from Simmons College Graduate School of Management and her B.S. from the University of Maine.

Ramy Farid, Ph.D.

President & CEO
Schrödinger

Dr. Ramy Farid joined Schrödinger in 2002 and serves as President & CEO and as a member of the board of directors. Prior to joining Schrödinger, Ramy was an Assistant Professor in the Chemistry Department at Rutgers University. He was an NIH Postdoctoral Fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania and received his Ph.D. in Chemistry from Caltech.

Rajeev Dadoo, Ph.D., MBA

Partner
SR One Ltd.

Rajeev joined SR One in 2004 and is an alum of the Kauffman Fellows Program.  His prior and current investments include Adheron, iPierian, True North, Propeller Health, Concert Pharmaceuticals, CyDex Pharmaceuticals, NeuroTherapeutics Pharma, Tranquis Therapeutics, IlluminOss Medical and Avhana Health. Rajeev also spent time with GSK's competitive excellence group, where he worked on company-wide strategic projects and operational projects. Prior to SR One, Rajeev worked at Genentech, where his role included technology and clinical development, and at Bio-Rad Laboratories in a product development role. In addition, Rajeev has worked in business development at Genome Therapeutics and was a co-founder of Unimicro Technologies. Rajeev received his B.A. in chemistry and mathematics from Knox College, his MBA from the Wharton School of the University of Pennsylvania and his Ph.D. in chemistry from Stanford University.

Steve Hall, Ph.D.

General Partner
Lilly Ventures

Dr. Steve Hall brings more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations to Lilly Ventures. Prior to joining Lilly Ventures, Steve was the co-founder and Senior Vice President, Research and Development, at Serenex, Inc. There, he recruited and led a team in developing a novel discovery technology and applied it to a project that advanced from a novel screen to first patient dosed in just over three years. This novel, orally-active Hsp90 inhibitor was the subject of strong interest across the industry and led to the acquisition of Serenex by Pfizer in April 2008. Prior to joining Serenex, Steve was Site Director, Sphinx Labs, Eli Lilly, where he oversaw lead generation efforts in the areas of combinatorial chemistry, automation, high-throughput screening, biomolecular research and information technology. There, he was a key member of a small team that developed and executed a strategy to partner Lilly’s expertise in high-throughput chemistry with three Japanese pharmaceutical companies with an aggregate value of more than $75 million. Steve currently sits on the boards of FORMA Therapeutics, Hydra Biosciences, InnoCentive, Nimbus Therapeutics and Cerulean Pharma. He also is a board observer at Avid Radiopharmaceuticals and Viamet.

Steve is the author of more than 40 papers and 60 papers and 60 patients. He received his B.S. in Chemistry from Central Michigan University and his Ph.D. in organic chemistry from the Massachusetts Institute of Technology.

Mark Iwicki

Chairman and CEO
Kala Pharmaceuticals

Mark Iwicki has 25 years of experience as a pharmaceutical industry leader managing all stages of drug development and commercialization in multiple therapeutic areas for several high-performance companies. Mark is the Chairman and CEO of Kala Pharmaceuticals and previously was CEO of Civitas Therapeutics which was sold to Acorda Therapeutics in 2014. Prior to joining Civitas, he was President and CEO of Blend Therapeutics, a nanotechnology oncology biotech company. He also served as President and CEO of Sunovion Pharmaceuticals, where he provided leadership for the successful launch of that company, which was created following the acquisition of Sepracor by Dainippon Sumitomo Pharmaceuticals. Mark also previously held key senior leadership roles with Sepracor and Novartis Pharmaceuticals. He currently also sits on the board of directors for Kala Pharmaceuticals, Allergen Research Corporation and Taris Biomedical.

Nikola Trbovic, Ph.D.

Executive Director, WRD and Principal
Pfizer Ventures

Nikola Trbovic, Ph.D. is Executive Director, WRD and Principal at Pfizer Ventures. Nikola is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. He currently has responsibility for Pfizer's investments in Arrakis, Artios, Cydan, Jnana, Nimbus and Palleon. Prior to his current role, Nikola held responsibilities for R&D technology investments, R&D strategy and early clinical portfolio management in Worldwide Research & Development at Pfizer. Nikola joined Pfizer from McKinsey Co., where he served as an Associate Principal and senior member of the Pharmaceuticals Practice, advising top pharmaceutical, biotech, and healthcare companies on a range of strategy, corporate finance and commercial topics across geographies and therapeutic areas. Nikola received a B.S. in Biochemistry from the University of Frankfurt, Germany, and holds a Ph.D. in Biochemistry and Molecular Biophysics from Columbia University.

Jeb Keiper, M.S., MBA

CEO
Nimbus Therapeutics

Jeb Keiper is the chief executive officer and a board member of Nimbus, having previously served as the chief business officer and chief financial officer. Prior to joining Nimbus, Jeb was VP of Business Development for GlaxoSmithKline (GSK) Oncology and a member of the Oncology Executive team, and responsible for defining and executing the business development strategy for GSK Oncology, including in-licensing transactions, acquisitions, strategic alliances, academic research relationships, alliance management and competitive intelligence. Alongside these responsibilities, Jeb was also named to lead the GSK-Novartis integration of the commercial oncology business valued at $16B. Prior to GSK, Jeb worked in business development at TransForm Pharmaceuticals, as well as for McKinsey. He began his career at Pfizer as a chemist. He received four degrees from the Massachusetts Institute of Technology (MIT): one degree in Chemistry, two degrees in Chemical Engineering and an MBA from the MIT Sloan School of Management.

George P. Vlasuk, Ph.D.

President and CSO
Navitor Pharmaceuticals

Dr. George P. Vlasuk is a scientifically trained executive with nearly 30 years of leadership experience in drug discovery and development at small and large biotechnology and pharmaceutical companies. George currently is President and CSO at Navitor Pharmaceuticals, where he previously served as CEO. Before joining Navitor, he served as CEO of Sirtris, a GlaxoSmithKline Company. Prior to Sirtris, George was Vice President, Metabolic Disease and Hemophilia Research, at Wyeth Pharmaceuticals. George also previously served as Chief Scientific Officer and Executive Vice President of Research and Development at Corvas International, prior to the merger of Corvas and Dendreon Corporation. Earlier in his career, George led a research team at Merck and Co., and was responsible for multiple discovery programs in the field of cardiovascular medicine. George is the author of more than 100 peer-reviewed scientific publications, book chapters and reviews, and 38 issued U.S. and foreign patents.

location

130 Prospect Street, Suite 301
Cambridge, MA 02139
USA

call US

857-999-2009